Safety alerts, recalls, shortages, labeling changes, and medication warnings from trusted authorities.
The FDA says some telehealth companies used false or misleading marketing for compounded GLP-1 drugs. Here is what that means for patients, how compounded products differ from approved drugs, and what to check before ordering online.
The FDA says promotional materials for Anktiva gave a misleading picture of what the bladder cancer drug can treat and how it is used. Here is what the drug is actually approved for, who it may fit, how it is given, and why the study behind the approval matters.
FDA has stepped up action against compounded GLP-1 weight-loss drugs sold online and through telehealth. Here’s what changed in 2026, why the agency says shortages no longer justify broad copycat compounding, what safety problems it has flagged, and how to protect yourself before buying.
FDA says Silintan capsules sold online nationwide contained undeclared meloxicam, an NSAID that can raise the risk of bleeding, ulcers, kidney injury, heart attack, and stroke in some users.
The FDA has classified a recall for certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors as Class I, its most serious recall type. The issue is falsely low glucose readings from some sensor lots. Here is what is affected, what is not, how to check your sensor, and what to do if a reading does not match how you feel.
Drug shortages remain a nationwide issue in early 2026. Here’s what it means when a medication appears on the FDA’s Drug Shortages list, how shortages differ from recalls, and what patients should do to protect their care.
The FDA has issued recent safety communications about compounded versions of popular GLP-1 drugs such as semaglutide and tirzepatide, warning of dosing errors, ingredient differences, and potential contamination. Here’s what patients and families should understand about the risks, legal limits, and how to protect themselves.
Federal telehealth flexibilities for prescribing ADHD stimulants were extended through December 31, 2025, while medication shortages continue into 2026. Here’s what patients and families across the United States should know about access, insurance, and practical next steps.
The FDA has updated its shortage listings and enforcement posture around compounded semaglutide and tirzepatide. Here’s what that could mean for patients who rely on these medications for diabetes or weight management.
Federal regulators say current evidence does not show a clear link between GLP-1 weight-loss drugs and suicidal thoughts. Here’s what the FDA reviewed, what the data show, and what patients should watch for.
As the FDA updates its policies around compounded versions of GLP-1 drugs like semaglutide and tirzepatide, patients may see changes in availability, pricing, and oversight. Here’s what the shift means for access, safety, and insurance coverage.
After criticism over how infant formula shortages and infant botulism recalls were handled, the FDA says it is strengthening recall oversight, improving communication, and moving faster when infant health is at risk. Here’s what that means for families.
Medical errors, medication mix-ups, and preventable infections remain major patient-safety concerns in the United States. Here’s what federal health agencies say patients and families can do to lower risks and improve care quality.
Drug recalls and medication shortages continue to affect patients nationwide. Here’s how to check if your medication is affected, what to do next, and where to find reliable updates from U.S. health agencies.
End of content
End of content
